arrow
A

Adeera Levin

University of British Columbia
H指数:103
被引数:8.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: insights from the CREDENCE trial

卡格列净在CKD患者中不同联合用药负担下的疗效和安全性具有一致性:来自CREDENCE试验的见解

2026-09-040
OAAI
Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy on CKD progression

ZENITH高蛋白尿试验的设计和基线特征:评估zibotentan/dapagliflozin对CKD进展有效性的研究

2026-08-040
OAAI
Combination Treatment for Management of Chronic Kidney Disease and Type 2 Diabetes: A Review and Practical Guidance

慢性肾脏病和2型糖尿病管理的联合治疗:综述与实践指南

2026-07-010
PRE
Global landscape of kidney health across Indigenous populations

土著居民肾脏健康的全球景观

2025-10-160
PRE
Rationale and Design of the International Prospective Study of CKD of Uncertain Etiology in Agricultural Communities

国际农业社区不明原因慢性肾脏病前瞻性研究的理由与设计

2025-06-300
OAAI
A Core Outcome Set for Trials in CKD: Report of the Standardized Outcomes in Nephrology–Chronic Kidney Disease (SONG-CKD) Stakeholder Workshops

慢性肾脏病临床试验的核心结局指标集:标准化肾病结局研究-慢性肾脏病(SONG-CKD)利益相关者工作坊报告

2025-01-230
PRE
Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

卡格列净在老年人中的心血管,肾脏和安全性结果: 来自CANVAS计划和cre登斯试验的联合分析

2025-01-090
PRE
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy

阿曲生坦在IgA肾病患者中的随机对照研究ALIGN的研究设计和基线特征

2025-01-011
OAAI
Progress of nations in the organisation of, and structures for, kidney care delivery between 2019 and 2023: cross sectional survey in 148 countries

各国在肾脏护理提供2019年和2023的组织和结构方面的进展: 148个国家的横断面调查

2024-10-141
OAAI